Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5034MR)

This product GTTS-WQ5034MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Heloderma suspectum
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5034MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ719MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ11104MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ2891MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ9502MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ10735MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ3248MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ14688MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ3278MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW